Close

ONK Therapeutics Brings in US Financial Experience with the Appointment of Dr. Allan Reine as Independent Non-Executive Director Mar 23, 2022 04:00AM
Pieris Pharma (PIRS), Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific Apr 26, 2021 08:14AM
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific Apr 26, 2021 08:00AM
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific Apr 26, 2021 08:00AM
Seattle Genetics (SGEN), Pieris Pharmaceuticals (PIRS) Announce Multi-Program Immuno-Oncology Pact Feb 9, 2018 06:45AM


Feb 9, 2018 06:45AM Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration
Feb 9, 2018 06:45AM Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration
Dec 20, 2017 08:00AM Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
May 3, 2017 07:11AM Pieris Pharma (PIRS), AstraZeneca (AZN) Announced Pact to Develop and Commercialize Anticalin-Based Inhaled Treatments for Respiratory Diseases
May 3, 2017 02:00AM Pieris Pharmaceuticals and AstraZeneca Collaborate to Develop and Commercialize Anticalin-Based Inhaled Treatments for Respiratory Diseases